Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Merck Serono to run research projects with BioMed X

Published: Thursday, April 04, 2013
Last Updated: Thursday, April 04, 2013
Bookmark and Share
Merck Serono is to run research projects at an innovation centre operated by BioMed X on the life science campus of the University of Heidelberg in Germany.

The new research lab will allow Merck Serono to run projects with interdisciplinary teams of young scientists, coached by a supervisor at Merck Serono and an experienced academic in an open-innovation lab facility.

Merck Serono said the researchers from leading academic institutions worldwide will be selected through assessment centres based on their ‘scientific expertise, creative energy, and passion for product-oriented pre-clinical research and development’.

Under the terms of the agreement signed by both companies, Merck Serono will fund and run its own research projects on new treatments for cancer in the biomedical research lab. No financial terms have been disclosed.

 ‘Our goal is to seed and boost early stage research projects by placing them into a vibrant environment, bringing in top young talent to work at the interface between industry and academia in one of the top European research hubs in Heidelberg,’ said Bernhard Kirschbaum, Head of Global Research and Early Development at Merck Serono. ‘We expect this concept can result in a constant flow of innovative projects and creative talent into Merck Serono.’

In addition to operating the innovation centre, BioMed X will be responsible for worldwide recruiting of young talents, providing education to teams and securing access to academic research infrastructure in Heidelberg.

‘I believe forming teams of top life science talents from around the world and providing experienced mentors from academia and industry is a critical step to success,’ said Christian Tidona, Founder and Managing Director of BioMed X.

BioMed X’s goal is to establish and run innovation centres in major innovation hubs worldwide.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck Serono and Intrexon Announce Agreement
Collaboration and license agreement will focus on developing a next generation CAR-T platform to generate several drug candidates.
Thursday, April 02, 2015
Merck Serono Appoints Luciano Rossetti
Appointment of Rossetti as Executive Vice President and Global Head of Research & Development.
Thursday, July 17, 2014
Merck Serono to Focus on Infertility Treatment
TocopheRx will focus on the development of oral follicle-stimulating hormone agonists for treatment of infertility.
Tuesday, December 03, 2013
Merck KGaA and Quintiles Announce Innovative Clinical Development Partnership
Agreement creates unique strategic collaboration for development and clinical trial execution.
Friday, May 17, 2013
Scientific News
Computational Model Finds New Protein-Protein Interactions
Researchers at University of Pittsburgh have discovered 500 new protein-protein interactions (PPIs) associated with genes linked to schizophrenia.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Bioreactors Ready for the Big Time
Bioreactors are passive filtration systems that can reduce nitrate losses from farm fields.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
‘Mini-Brains’ to Study Zika
Novel tool expected to speed research on brain and drug development.
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Common Class of Cancer Drugs May Not Lead to Cognitive Decline
UCLA study refutes 2015 research suggesting anthracyclines could cause memory loss, other impairments.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!